TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01143857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2.0 mg/day or Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2.0 mg/day or Placebo
Study: NCT00058292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
Study: NCT00196976

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
Study: NCT00060424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT02870283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Study: NCT02374151

Intervention type: DEVICE
Intervention: Electrohysterography
Description: The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
Study: NCT00603330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal Stem Cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal Stem Cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal Stem Cell infusion
Study: NCT04104386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telomere Disclosure Impact
Description: Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
Study: NCT01276262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, repeated doses for 21 days (2 x 50mg BID)
Study: NCT02469272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Administration of frozen fecal materials into gastrointestinal tract
Study: NCT01276262

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon® 30 (Oral contraceptive)
Description: Oral tablets, repeated doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon® 30 (Oral contraceptive)
Description: Oral tablets, repeated doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets BID, repeated doses for 21 days
Study: NCT01111695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApisSept
Description: honey and ionic silver based dressing
Study: NCT00239733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-D
Description: 30-minute infusion administered in an outpatient setting
Study: NCT03055117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise rehabilitation
Description: Group- based physiotherapy-led exercise rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual exercise rehabilitation
Description: Individual physiotherapy-led exercise rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Supervised home exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Supervised home exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Supervised home exercise
Study: NCT04676620

Intervention type: PROCEDURE
Intervention: CK surgery
Description: CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.

Intervention type: PROCEDURE
Intervention: CK surgery
Description: CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
Study: NCT01315171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium chain triglycerides
Description: 4 tablespoons/day for 2 weeks
Study: NCT04006951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)
Study: NCT00804466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoE6
Description: HPV oncoprotein assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVA System
Description: low-cost colposcope
Study: NCT00872235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
Study: NCT00855621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the subthalamic nucleus
Description: Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the subthalamic nucleus
Description: Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
Study: NCT03375034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC 20mg
Description: Oral administration of one NDMC 20mg capsule and two Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC60mg
Description: Oral administration of three NDMC 20mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam 1.5mg
Description: Oral administration of three clonazepam 0.5mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of three Placebo capsules
Study: NCT01992588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
Study: NCT03401775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Description: Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
Study: NCT02194595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal insulin and exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin and bolus insulin
Study: NCT00583336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShuntCheck
Description: Thermal dilution test for CSF flow
Study: NCT03549026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
Study: NCT01583361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+S-1
Description: S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Oxaliplatin/S-1（SOX）
Description: S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
Study: NCT04187313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSTEP2 intervention package
Description: The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients.
Study: NCT01139580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene Foam
Description: Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
Study: NCT01164904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amg 181
Description: Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
Study: NCT03797677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MN 4000
Description: Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
Study: NCT03796962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: Oral dose
Study: NCT04618003

Intervention type: BEHAVIORAL
Intervention: Adaptation of autonomic nervous system to activity in virtual reality
Description: heart rate variability assessed at rest and during a physical activity in virtual reality.

Intervention type: BEHAVIORAL
Intervention: Adaptation of autonomic nervous system to activity in virtual reality
Description: heart rate variability assessed at rest and during a physical activity in virtual reality.
Study: NCT03796962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XEN1101
Description: Oral dose
Study: NCT02270138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-to-music video program
Description: Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
Study: NCT02104843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir, Asunaprevir and BMS-791325 FDC
Study: NCT01104649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Study: NCT02104843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT02730949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: Treated group

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Control group
Study: NCT02931461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Study: NCT00185159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: tablets
Study: NCT04618003

Intervention type: BEHAVIORAL
Intervention: Adaptation of autonomic nervous system to activity in virtual reality
Description: heart rate variability assessed at rest and during a physical activity in virtual reality.
Study: NCT02730949

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Control group
Study: NCT03789838

Intervention type: OTHER
Intervention: Sepsis rapid response team
Description: Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
Study: NCT01485146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: escalating doses
Study: NCT03661762

Intervention type: DEVICE
Intervention: CAVA
Description: prototype device for monitoring dizziness
Study: NCT03802461

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Feces from healthy donor
Study: NCT00584415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP ablation + PV isolation
Description: All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
Study: NCT02739399

Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Intravenous administration
Study: NCT03980730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon 5 mg capsule administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule administered orally, once daily
Study: NCT00428948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as tablets.
Study: NCT03406273

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral Spinal (CS) radiation
Description: Surgery plus Cerebral Spinal (CS) radiation
Study: NCT00185159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Tablets
Study: NCT04084704

Intervention type: DEVICE
Group type: OTHER
Intervention: Cingal
Description: Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
Study: NCT01680263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs/Physical therapy
Description: Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
Study: NCT03548779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit prep
Description: Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit prep
Description: Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: usual care + exome seq
Description: Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: usual care + exome seq
Description: Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
Study: NCT00357942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine solution for injection
Description: morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
Study: NCT03406273

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral Spinal (CS) radiation
Description: Surgery plus Cerebral Spinal (CS) radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (SRS)
Description: Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
Study: NCT02700347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide